ID: MRFR/MED/1766-CR | February 2021 | Region: Global | 47 pages
Market Research Future (MRFR) believes that the U.S. Uterine Fibroid Market 2020 can hit USD 39,993.2 Million by 2022-end. It is also projected that the U.S. uterine fibroid market size can escalate at a rate of 3.24% between 2016 and 2022 (analysis period).
In response to the COVID-19 outbreak, the medical industry has boosted its efforts to revive services and operations even as the lockdown situation still persists. The US uterine fibroid industry has been gearing up to deal with the issues arising following the SARS-CoV-2 pandemic, some of which are economic downfall, weakened demand among end-users and revenue loss. Even lower demand for uterine fibroid treatment among women has been noted post the novel coronavirus, given the expensive nature of the same.
However, leading manufacturers in the US are working on ramping up their production capacity, while also trying out new methods to maintain their business, including collaborations with other vendors, open-source designing of equipment, and deploying highly skilled employees to meet with the evolving needs. These initiatives by the top firms in the country in the face of the pandemic can be favorable for the US uterine fibroid market in the ensuing years.
Surging Cases and Improving Awareness Level to Foster Growth
Uterine fibroid cases among women have escalated rapidly in recent years, giving a significant push to market growth in the United States. A study confirms that in October 2018, the prevalence rate for the same was 240.3 per 10,000 women, aged between 45 and 49 years. The case is further bolstered by the rising availability of efficient and innovative therapies and the high purchasing power of women in the country.
Patients are increasingly opting for minimally or non-invasive uterine fibroid procedures, for which players are focusing on developing types of devices that ensure the same. The high preference for these procedures is due to the fact that these ensure reduced post-operative pain and also mean faster recovery. A number of renowned contenders in the country are spending considerably on R&D for launching advanced minimally and non-invasive surgical devices and instruments, which can ultimately translate into significant market growth.
Various initiatives are taken up by the government as well as private firms to raise the awareness level among the mass about early uterine fibroids diagnosis as well as treatment. Lately, there has been a striking growth in awareness efforts in the US, with some of the most prominent programs including the HealthyWomen.org, White Dress Project, Center for Innovative GYN Care and Fibroids Project.
Rising Education and Awareness Levels to be a Significant Opportunity
Improving education and awareness levels with regard to uterine fibroid treatment can present attractive opportunities to the leading firms in the US market. Studies show that women with uterine fibroid are faced with low quality of life and many of them are largely undiagnosed, which has pushed the need for higher level of education and awareness.
Expensive Treatment Options to Hinder Market Growth
The currently available treatments for uterine fibroids are mainly expensive and surgical (invasive), which can restrain the otherwise solid market growth in the following years.
Higher Risks Associated with Morcellators to be a Challenge
Complications arising from using morcellators can be a major challenge in the U.S. uterine fibroid market. Laparoscopic power morcellators are primarily used during myomectomy and hysterectomy procedures, but they can cause complications like metastatic leiomyosarcoma cancer.
Surge in Subserosal Uterine Fibroid Cases to Ensure Growth
Types of uterine fibroid conditions are submucosal fibroids, intramural fibroids, subserosal fibroids, and others. Subserosal uterine fibroids cases have increased in recent years, owing to which the number of hysterectomy surgeries has also risen in number, which lands the segment in the lead.
Ultrasound to be the Most Preferred Diagnosis Option
Diagnosis-based key segments are computed tomography (CT), medical resonance imaging (MRI) scanners, ultrasounds and more. Ultrasound remains in the lead as this is an incisionless procedure that is mostly preferred by physicians. Their high demand is the result of the provision of minimal pain, high efficacy and lower chances of infection as compared to other diagnosis options.
Hysterectomy to be the Leading Treatment-Based Segment
Treatment-wise market categories are magnetic resonance guided focused ultrasound, uterine fibroid embolization, endometrial ablation, myolysis, myomectomy and hysterectomy. Between these, hysterectomy is the leading treatment-based segment in the U.S. uterine fibroid market and could touch USD 8,042.3 million by 2022.
The US Uterine Fibroid Market Picks up Speed as Cases Accelerate
The U.S. uterine fibroids market seems to be making steady progress and can procure a growth rate of 3.24% between 2016 and 2022. Texas, California, New York and Florida are some of the top performing states in the country, since these have maximum prevalence of uterine fibroids.
To retain their dominance, players are emphasizing on product differentiation. Most of the players are also focused on acquisitions and mergers to expand their product portfolio, while integrating the knowledge and expertise base being the other objective. For instance, in May 2020, Minerva Surgical acquired Intrauterine Health franchise owned by Boston Scientific. Minerva's product range will offer medical practitioners with a vast portfolio required to treat Abnormal Uterine Bleeding. The newly formed range of minimally invasive tools will be a combination of Minerva Endometrial Ablation System, an innovative uterine fibroid ablation device, with Genesys HTA Endometrial Ablation System.
The uterine leiomyoma uterine fibroids market in the country also benefits from the rising preference for minimally invasive surgeries that help reduce the pain associated with the condition. As a result, there has been significant growth in the US uterine fibroid embolization market since UFE is a minimally invasive treatment facilitates treatment of fibroid tumors present in the uterus. Furthermore, the US market is largely favored by the supportive regulatory approvals for the new surgeries and treatment lines developed by firms.
Uterine fibroid affects close to 10% of women in the US in their reproductive years, while the prevalence rate among asymptomatic women ranges from 2% to 22% and among infertile women, it goes up to 40%. The escalating prevalence rate in the country can be owing to heredity or simply an unhealthy lifestyle with bad eating habits, and is working to enhance the uterine fibroid market size.
Players Focus on R&D Activities as Need for Innovative Devices Rise
AbbVie Inc. (U.S.) has emerged as one of the top uterine fibroid vendors, known for addressing difficult-to-cure disorders by focusing on extensive R&D activities. The company’s expertise in uterine fibroid embolization and exophytic uterine fibroid in recent years has been impressive. Recently, AbbVie even managed to get FDA approval for its drug for uterine fibroid-associated heavy bleeding. The drug, under the brand name Orilissa, primarily caters to uterine fibroid treatments or endometriosis.
|Market Size||USD 39,993.2 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Diagnosis and Treatment|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Boston Scientific Corporation (US), Cook Medical Inc. (US), GE Healthcare (U.K.), AstraZeneca (England), AbbVie Inc. (U.S.), Hologic (U.S.)|
|Key Market Opportunities||Rising Education and Awareness Levels to be a Significant Opportunity|
|Key Market Drivers||Surging Cases and Improving Awareness Level to Foster Growth|
Frequently Asked Questions (FAQ) :
By Type, the intramural fibroids segment and by Treatment, the hysterectomy segment hold larger shares in the Global Uterine Fibroid Market.
Rising prevalence of the condition due to heredity reasons, increasing numbers of treatments to cure the disease, and emergence of novel therapeutics are major drivers of the Global Uterine Fibroid Market.
North America holds the largest share in the Global Uterine Fibroid Market, followed by Europe and the Asia Pacific, respectively.
Cook Medical Inc. (U.S.), AstraZeneca (U.K), Boston Scientific Corporation (U.S.), AbbVie Inc. (U.S.), GE Healthcare (U.K), Hologic (U.S.), C. R. Bard, Inc. (U.S.), CooperSurgical Inc. (U.S.), Bayer AG (Germany), and F. Hoffmann-La Roche Ltd (Switzerland), are some of the major players operating in the uterine fibroid market.
Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global uterine fibroid market adopt to gain a larger competitive advantage.